ANXA5

2 papers1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

A gene’s or a process’s line counts the gene with the processes named after it, as NLRP3 with the NLRP3 inflammasome, and the trials of drugs aimed at it.

1 lab

Humans1
Animals1

Interventions

Caffeic acid

downin mouse cells1

1 study

Caffeic acid decreases ANXA5 in mouse cells.
“covalent binding of CA to Annexin A5 protein triggered its degradation, PKCθ deactivation, and the inhibition of the NF-κB inflammatory pathway in senescent cells.”
Cellsin senescent cells
Caffeic Acid Acts as a Potent Senomorphic and Alleviates Inflammation and Lung Fibrosis by Covalently Targeting Annexin A5 Protein in Mice
Exploration (Beijing, China)12 Dec 2025